For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their potential risks. Within this legacy, audiences have been educated about the balance between therapeutic benefit and adverse effects, fostering a baseline awareness of how pharmaceutical interventions interact with human biology. This broad educational heritage naturally extends to more specialized areas of concern, particularly when a widely used therapy is linked to serious, long-term outcomes that require legal and occupational scrutiny. One such therapy is Tysabri (natalizumab), a medication prescribed for certain autoimmune conditions. Over time, clinical experience and post-market surveillance have identified a rare but severe risk: Progressive Multifocal Leukoencephalopathy (PML), a brain infection associated with the reactivation of the JC virus. This risk has transformed the conversation from general health education into a focused occupational and legal concern. For individuals who have been exposed to Tysabri—whether as patients, caregivers, or healthcare workers involved in administration—the potential for PML introduces questions about monitoring, liability, and recourse. In Massachusetts, the statute of limitations imposes strict deadlines for filing claims related to such exposure. This pivot from general health awareness to the specific legal and occupational dimensions of Tysabri and PML risk underscores the need for timely action.
Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. In FAERS adverse-event reports for Tysabri, frequently reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis itself, the onset of new or worsening neurological signs in a patient on Tysabri should prompt immediate evaluation for PML. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid.
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion molecule VLA-4 on lymphocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial in multiple sclerosis, but it also impairs immune surveillance against JCV. Under normal conditions, JCV is controlled by the immune system; with reduced T-cell trafficking into the brain, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For patients in Massachusetts who have developed PML after Tysabri treatment, attorney-related considerations center on the adequacy of warnings provided by the manufacturer and healthcare providers. The prescribing information includes a boxed warning and detailed risk factors, but questions may arise about whether patients were adequately informed of the specific risk of PML, the importance of monitoring for symptoms, and the need for prompt discontinuation if symptoms appear. The timeline between exposure and documented harm is critical: PML can develop months to years after starting Tysabri, and the label notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who were not warned about this latency period or who were not monitored appropriately may have a basis for legal action. The statute of limitations for Tysabri-related claims in Massachusetts is governed by state law, which generally requires that a lawsuit be filed within three years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be the date of diagnosis or the date when symptoms first became apparent and were linked to Tysabri. Given the progressive nature of PML, early symptoms such as cognitive changes or gait disturbance might be mistaken for multiple sclerosis relapse, potentially delaying recognition. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline based on their specific circumstances.
In summary, Tysabri carries a well-documented risk of PML, with identified risk factors including anti-JCV antibody status, treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be subtle and overlap with multiple sclerosis symptoms, making timely diagnosis challenging. For affected patients in Massachusetts, legal considerations include the adequacy of warnings, the timeline of exposure and harm, and the applicable statute of limitations. A thorough review of medical records and prescribing information is essential for evaluating potential claims.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Massachusetts, the statute of limitations generally requires that a lawsuit be filed within three years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be the date of diagnosis or when symptoms first became apparent and were linked to Tysabri. Given the progressive nature of PML, early symptoms might be mistaken for multiple sclerosis relapse, potentially delaying recognition. It is crucial to consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline based on your specific circumstances.
The prescribing information identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressant medications are at highest risk.
Symptoms of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Because these symptoms overlap with multiple sclerosis, any new or worsening neurological signs in a patient on Tysabri should prompt immediate evaluation for PML, including brain MRI and detection of JCV DNA in cerebrospinal fluid.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.